Add Alzheimer's disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new ...

People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared ...

Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...

Semaglutide, the active ingredient found in Ozempic and Wegovy, may reduce the risk of Alzheimer’s disease, a new study published Thursday morning finds.

Type-2 diabetes patients taking the active ingredient in the drugs, semaglutide, "had a significantly lower risk" of ...

The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...

Novo Nordisk NVO has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded versions of ...

The GLP-1 phenomenon is making the fragmentation and dysfunction of the U.S. health care system even more apparent.

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...

Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...

On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial.

FDA approval: Ozempic is FDA-approved for Type 2 diabetes, while Wegovy is FDA-approved for weight loss. Cost: Ozempic is ...